Development of a dosing strategy for enoxaparin in obese patients.
about
Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical reviewAnalysis of population pharmacokinetic data using NONMEM and WinBUGS.Enoxaparin use in pregnancy: state of the art.The Daniel K. Inouye College of Pharmacy Scripts: Obesity: The Drug Dose Debate.A comprehensive model for the humoral coagulation network in humans.Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.Gentamicin pharmacokinetics and pharmacodynamics during short-daily hemodialysis.What is the best size descriptor to use for pharmacokinetic studies in the obese?Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes.Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation.Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years oldAdministration of enoxaparin by continuous infusion in a naturalistic setting: analysis of renal function and safety.Venous thromboembolism in trauma: an update for the intensive care unit practitioner.Pharmacokinetics of L-arginine in adults with moderately severe malaria.Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE studyEffect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects.Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising eventsThe effects of obesity on drug pharmacokinetics in humans.Anticoagulating obese patients in the modern era.What do we learn from repeated population analyses?A growing problem: implications of obesity on the provision of trauma care.Dosing of enoxaparin for venous thromboembolism prophylaxis in obese patients.Risk factors for polyuria in a cross-section of community psychiatric lithium-treated patients.Current dosing of low-molecular-weight heparins does not reflect licensed product labels: an international survey.Clinical decision support implemented with academic detailing improves prescribing of key renally cleared drugs in the hospital setting.Evaluation and Pharmacokinetics of Treatment Dose Enoxaparin in Hospitalized Patients With Morbid Obesity.Pharmacokinetics of intravenously administered levofloxacin in men and women.Fixed-dose enoxaparin after bariatric surgery: the influence of body weight on peak anti-Xa levels.Drug dosing in obese adults.Low-molecular-weight heparin in pregnancy: state of the art.Effect of body weight on efficacy and safety of direct oral anticoagulants in the treatment of patients with acute venous thromboembolism: a meta-analysis of randomized controlled trials.A reduction in between subject variability is not mandatory for selecting a new covariate.Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint.The clinical utility of pharmacometric models.
P2860
Q26992262-15CEC772-8865-455D-A783-B97E9FACBD3EQ30982415-640A258F-FD4B-44EC-A7B1-79DE74159926Q33386499-2BFEF8F7-DADF-4C81-BB8D-2EF3653DC510Q33763123-1A20BACF-1ED3-4441-8D12-5744AF74E0D6Q34986144-48716229-9D8F-4662-BF64-B8C77E634E8AQ34996894-2D4D3137-5CC4-4D0F-8F87-22F5F89425F1Q35001792-42E95EFE-FD09-44A7-8445-D716646BFA55Q35826324-790609B4-4B3A-4BFF-A750-A9852435B739Q35826839-1D8CE117-2B10-4F39-8260-82226D4BE707Q35827649-DCF855F2-AA5F-48BE-A122-A526F46A122FQ36102602-ECF6B450-A1ED-451A-AFC7-AFA16CDAAC7BQ36128828-D1C668BD-1D6D-4454-95FB-B059EB1943EAQ36720728-159EA88E-071A-405D-850F-C1EC7107DAEFQ36993439-51DCCC98-8A30-4429-A778-2E1B1679B19FQ37142429-FFAF5F33-A3DA-4371-83C3-BC06B2A6144CQ37353441-3A9CA4EE-C3B4-4D87-8DC4-6D7189333F2AQ37471067-C9B58B94-AFB0-4D53-8393-51800917792FQ37854751-DF2D93A7-FC07-4CCD-9877-204D7F5C9F1DQ37919151-EA2EBC4D-C135-48AA-8009-13CB4E1601CDQ38137268-212E7ACC-09B1-4D23-95EC-2CD28740B57CQ38149772-8378C852-94B4-48B4-B528-F941D33845F9Q38168477-50140A51-3FDB-4285-BDCD-D515493EF6BFQ39152568-54CCCCFD-B627-409F-9BD6-EE89F2CAD0F6Q40067699-4AA30A1F-2F55-4B36-82A3-70393043BC04Q41314653-A5ADC841-05CD-439D-93A2-BDACF3E210B2Q41559648-EFA6C89F-0E8C-48E0-A26B-40280452A033Q42668977-45A20F8C-AD28-4627-8C80-E87DF74EE452Q43426032-34D0A5A1-8357-40B6-A9C3-1BF31080C5B0Q47154923-C8BB15E7-49FB-48E9-A71A-3E847F15EA96Q47370577-ACA54BD9-69F7-4C23-BEE1-770DDB3FE3EBQ47406652-3B2E4DB9-4A9B-4B5A-B0DE-80CA51B30569Q47414092-734023F9-C630-4481-A5CA-311DA27041B4Q47431339-E6BD3E20-AF0B-454C-A672-78D3B0E38767Q52594703-E2C60FAA-472D-4AB9-84A2-2A065F9F6F88
P2860
Development of a dosing strategy for enoxaparin in obese patients.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Development of a dosing strategy for enoxaparin in obese patients.
@ast
Development of a dosing strategy for enoxaparin in obese patients.
@en
type
label
Development of a dosing strategy for enoxaparin in obese patients.
@ast
Development of a dosing strategy for enoxaparin in obese patients.
@en
prefLabel
Development of a dosing strategy for enoxaparin in obese patients.
@ast
Development of a dosing strategy for enoxaparin in obese patients.
@en
P2860
P1476
Development of a dosing strategy for enoxaparin in obese patients.
@en
P2093
Bruce Green
P2860
P304
P356
10.1046/J.1365-2125.2003.01849.X
P407
P577
2003-07-01T00:00:00Z